1
|
Liebermann A, Schultheis A, Faber F, Rammelsberg P, Rues S, Schwindling FS. Impact of post printing cleaning methods on geometry, transmission, roughness parameters, and flexural strength of 3D-printed zirconia. Dent Mater 2023; 39:625-633. [PMID: 37179237 DOI: 10.1016/j.dental.2023.05.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 04/12/2023] [Accepted: 05/02/2023] [Indexed: 05/15/2023]
Abstract
OBJECTIVE To analyze the impact of different post printing cleaning methods on geometry, transmission, roughness parameters, and flexural strength of additively manufactured zirconia. METHODS Disc-shaped specimens (N = 100) were 3D-printed from 3 mol%-yttria-stabilized zirconia (material: LithaCon 3Y 210; printer: CeraFab 7500, Lithoz) and were cleaned with five different methods (n = 20): (A) 25 s of airbrushing with the dedicated cleaning solution (LithaSol 30®, Lithoz) and 1-week storage in a drying oven (40 °C); (B) 25 s airbrushing (LithaSol 30®) without drying oven; (C) 30 s ultrasonic bath (US) filled with Lithasol30®; (D) 300 s US filled with LithaSol 30®; (E) 30 s US filled with LithaSol 30® followed by 40 s of airbrushing (LithaSol 30®). After cleaning, the samples were sintered. Geometry, transmission, roughness (Ra, Rz), characteristic strengths (σ0), and Weibull moduli (m) were analyzed. Statistical analyses were performed using Kolmogorov-Smirnov-, t-, Kruskal-Wallis-, and Mann-Whitney-U-tests (α < 0.05). RESULTS Short US (C) resulted in the thickest and widest samples. Highest transmission was found for US combined with airbrushing (E, p ≤ 0.004), followed by D and B (same range, p = 0.070). Roughness was lowest for US combined with airbrushing (E, p ≤ 0.039), followed by A and B (same range, p = 0.172). A (σ0 = 1030 MPa, m = 8.2), B (σ0 = 1165 MPa, m = 9.8), and E (σ0 = 1146 MPa, m = 8.3) were significantly stronger (p < 0.001) and substantially more reliable than C (σ0 = 480 MPa, m = 1.9) and D (σ0 = 486 MPa, m = 2.1). SIGNIFICANCE For 3D-printed zirconia, cleaning strategy selection is important. Airbrushing (B) and short US combined with airbrushing (E) were most favorable regarding transmission, roughness, and strength. Ultrasonic cleaning alone was ineffective (short duration) or detrimental (long duration). Strategy E could be particularly promising for hollow or porous structures.
Collapse
Affiliation(s)
- A Liebermann
- Department of Prosthetic Dentistry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
| | - A Schultheis
- Department of Prosthetic Dentistry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - F Faber
- Department of Prosthetic Dentistry, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - P Rammelsberg
- Department of Prosthetic Dentistry, Heidelberg University Hospital, Heidelberg, Germany
| | - S Rues
- Department of Prosthetic Dentistry, Heidelberg University Hospital, Heidelberg, Germany
| | - F S Schwindling
- Department of Prosthetic Dentistry, Heidelberg University Hospital, Heidelberg, Germany; Department of Prosthetic Dentistry, Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
2
|
Michels S, Scheffler M, Wagener S, Plenker D, Scheel A, Nogová L, Schultheis A, Fischer RN, Abdulla DS, Riedel R, Bunck A, Kobe C, Baus W, Merkelbach-Bruse S, Sos ML, Büttner R, Wolf J. Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precis Oncol 2018; 2:1-6. [DOI: 10.1200/po.18.00121] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Sebastian Michels
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Matthias Scheffler
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Svenja Wagener
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Dennis Plenker
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Andreas Scheel
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Lucia Nogová
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Anne Schultheis
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Rieke N. Fischer
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Diana S.Y. Abdulla
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Richard Riedel
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Anne Bunck
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Carsten Kobe
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Wolfgang Baus
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Sabine Merkelbach-Bruse
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Martin L. Sos
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Reinhard Büttner
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| | - Jürgen Wolf
- All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany
| |
Collapse
|
3
|
Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 2016; 6:10577-85. [PMID: 25868855 PMCID: PMC4496376 DOI: 10.18632/oncotarget.3387] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 02/15/2015] [Indexed: 12/12/2022] Open
Abstract
Background While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. Patients and Methods 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients. Results 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations. Conclusion ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.
Collapse
Affiliation(s)
- Matthias Scheffler
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Anne Schultheis
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Cristina Teixido
- Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Sebastian Michels
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Santiago Viteri
- Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany
| | - Sabine Merkelbach-Bruse
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rieke Fischer
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Jana Fassunke
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Martin Sebastian
- Department of Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany
| | - Monika Serke
- Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | - Britta Kaminsky
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Winfried Randerath
- Clinic for Pneumology and Allergology Center for Sleep Medicine and Respiratory Care, Bethanien Hospital, Solingen, Germany
| | - Ulrich Gerigk
- Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany
| | - Yon-Dschun Ko
- Johanniter Hospital, Evangelical Clinics of Bonn, Bonn, Germany
| | - Stefan Krüger
- Clinic for Pneumology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Roland Schnell
- Practice for Internistic Oncology and Hematology, Frechen, Germany
| | - Achim Rothe
- Practice for Hematology and Oncology Mainka/Dietze/Rothe, Cologne, Germany
| | | | - Lukas Heukamp
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rafael Rosell
- Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain.,Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.,Molecular Oncology Research (MORe) Foundation, Barcelona, Spain
| | - Reinhard Büttner
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology Köln Bonn, Cologne, Germany.,Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
4
|
Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Gruenewald I, Marra A, Schultheis A, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel W, Wiewrodt R, Hartmann W. Die prognostische Wertigkeit der Expression von PD1 und PDL1 im nicht kleinzelligen Lugenkarzinom. Pneumologie 2016. [DOI: 10.1055/s-0036-1571966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Eminaga O, Semjonow A, Eltze E, Bettendorf O, Schultheis A, Warnecke-Eberz U, Akbarov I, Wille S, Engelmann U. Analysis of topographical distribution of prostate cancer and related pathological findings in prostatectomy specimens using cMDX document architecture. J Biomed Inform 2015; 59:240-7. [PMID: 26707451 DOI: 10.1016/j.jbi.2015.12.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 12/10/2015] [Accepted: 12/13/2015] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Understanding the topographical distribution of prostate cancer (PCa) foci is necessary to optimize the biopsy strategy. This study was done to develop a technical approach that facilitates the analysis of the topographical distribution of PCa foci and related pathological findings (i.e., Gleason score and foci dimensions) in prostatectomy specimens. MATERIAL & METHODS The topographical distribution of PCa foci and related pathologic evaluations were documented using the cMDX documentation system. The project was performed in three steps. First, we analyzed the document architecture of cMDX, including textual and graphical information. Second, we developed a data model supporting the topographic analysis of PCa foci and related pathologic parameters. Finally, we retrospectively evaluated the analysis model in 168 consecutive prostatectomy specimens of men diagnosed with PCa who underwent total prostate removal. The distribution of PCa foci were analyzed and visualized in a heat map. The color depth of the heat map was reduced to 6 colors representing the PCa foci frequencies, using an image posterization effect. We randomly defined 9 regions in which the frequency of PCa foci and related pathologic findings were estimated. RESULTS Evaluation of the spatial distribution of tumor foci according to Gleason score was enabled by using a filter function for the score, as defined by the user. PCa foci with Gleason score (Gls) 6 were identified in 67.3% of the patients, of which 55 (48.2%) also had PCa foci with Gls between 7 and 10. Of 1173 PCa foci, 557 had Gls 6, whereas 616 PCa foci had Gls>6. PCa foci with Gls 6 were mostly concentrated in the posterior part of the peripheral zone of the prostate, whereas PCa foci with Gls>6 extended toward the basal and anterior parts of the prostate. The mean size of PCa foci with Gls 6 was significantly lower than that of PCa with Gls>6 (P<0.0001). CONCLUSION The cMDX-based technical approach facilitates analysis of the topographical distribution of PCa foci and related pathologic findings in prostatectomy specimens.
Collapse
Affiliation(s)
- Okyaz Eminaga
- Dept. of Urology, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany.
| | - Axel Semjonow
- Prostate Center, Dept. of Urology, University Hospital Muenster, Albert-Schweitzer-Campus 1, D-48149 Muenster, Germany
| | - Elke Eltze
- Institute for Pathology Saarbrücken-Rastpfuhl, Rheinstrasse 2, D-66113 Saarbrücken, Germany
| | - Olaf Bettendorf
- Institute of Pathology and Cytology, Technikerstrasse 14, D-48465 Schüttorf, Germany
| | - Anne Schultheis
- Institute for Pathology, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany
| | - Ute Warnecke-Eberz
- Department for Visceral Surgery, University Hospital Cologne, Kerpener Straße 62, D-50937 Cologne, Germany
| | - Ilgar Akbarov
- Dept. of Urology, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany
| | - Sebastian Wille
- Dept. of Urology, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany
| | - Udo Engelmann
- Dept. of Urology, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany
| |
Collapse
|
6
|
Michels S, Schultheis A, Scheffler M, Rosner T, Merkelbach-Bruse S, Heukamp L, Engel-Riedel W, Serke M, Krüger S, Benedikter J, Gerigk U, Schulte W, Draube A, Ko Y, Büttner R, Wolf J. Ret Translocation in Adenocarcinoma of the Lung. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Eisert A, Scheffler M, Michels S, Schultheis A, König K, Merkelbach-Bruse S, Serke M, Ko Y, Gerigk U, Geist T, Heukamp L, Büttner R, Wolf J. Genetic Variability and Clinical Presentation of Patients with Non-Small Cell Lung Cancer (Nsclc) Harboring Met-Amplifications. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Abstract
Recent advances in the treatment of non-small cell lung cancer (NSCLC) are based on the identification of so-called driver mutations, resulting in a more personalized treatment setting. Currently about 15% of NSCLC patients benefit from improved treatment protocols based on the genetic background of the tumor. In the last few years cancer immunotherapy has returned to the center of attention and comprises a variety of treatment approaches incorporating adaptive, as well as innate immunity. Current strategies involve the use of monoclonal antitumor antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and NK cells as well as the blockade of so-called immune checkpoints (immune inhibitory pathways). Especially the combination of current treatments with immunotherapy seems promising to achieve highly potent antitumor effects. However, a profound understanding of the dynamic and complex interaction between lung cancer and the host immune system and especially its immune checkpoints is the foundation to identify potential biomarkers for a personalized cancer immunotherapy approach.
Collapse
Affiliation(s)
- A Schultheis
- Institut für Pathologie, CIO Köln Bonn, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln.
| | | | | |
Collapse
|
9
|
Schultheis A, Reichwein F, Nebelung W. Ventraler Schulterschmerz nach Leitersturz. Arthroskopie 2010. [DOI: 10.1007/s00142-010-0574-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009; 119:3011-23. [PMID: 19741298 DOI: 10.1172/jci39065] [Citation(s) in RCA: 246] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2009] [Accepted: 07/15/2009] [Indexed: 12/29/2022] Open
Abstract
Cytokines orchestrate the tumor-promoting interplay between malignant cells and the immune system. In many experimental and human cancers, the cytokine TNF-alpha is an important component of this interplay, but its effects are pleiotropic and therefore remain to be completely defined. Using a mouse model of ovarian cancer in which either TNF receptor 1 (TNFR1) signaling was manipulated in different leukocyte populations or TNF-alpha was neutralized by antibody treatment, we found that this inflammatory cytokine maintained TNFR1-dependent IL-17 production by CD4+ cells and that this led to myeloid cell recruitment into the tumor microenvironment and enhanced tumor growth. Consistent with this, in patients with advanced cancer, treatment with the TNF-alpha-specific antibody infliximab substantially reduced plasma IL-17 levels. Furthermore, expression of IL-1R and IL-23R was downregulated in CD4+CD25- cells isolated from ascites of ovarian cancer patients treated with infliximab. We have also shown that genes ascribed to the Th17 pathway map closely with the TNF-alpha signaling pathway in ovarian cancer biopsy samples, showing particularly high levels of expression of genes encoding IL-23, components of the NF-kappaB system, TGF-beta1, and proteins involved in neutrophil activation. We conclude that chronic production of TNF-alpha in the tumor microenvironment increases myeloid cell recruitment in an IL-17-dependent manner that contributes to the tumor-promoting action of this proinflammatory cytokine.
Collapse
Affiliation(s)
- Kellie A Charles
- Centre for Cancer and Inflammation, Institute of Cancer, Barts and The London School of Medicine and Dentistry,Queen Mary University of London, Charterhouse Square, London, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Schultheis A, Reichwein F, Nebelung W. [Frozen shoulder syndrome]. MMW Fortschr Med 2009; 151:36-37. [PMID: 19722459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- A Schultheis
- Abt. Arthroskopie - Sportorthopädie, Marienkrankenhaus Kaiserswerth, Düsseldorf.
| | | | | |
Collapse
|
12
|
Abstract
The condition of shoulder stiffness is often called adhesive capsulitis or frozen shoulder. It is regarded as a distinct clinical entity showing a benign and regular course. The major clinical feature is significant reduction in both active and passive range of motion (ROM) accompanied by stage-dependent pain, allowing for a clinical diagnosis. There are primary and secondary forms, the former having an unknown etiology and increased occurrence in patients with metabolic disorders and the latter being seen with prior injury or operation. Three stages, each lasting 4-6 months, mark the clinical course. The progression of the disease is self-limiting and may occasionally resolve in partial restitution. In the first stage ("freezing"), the shoulder continuously loses passive motion and causes worsening pain. Continuing stiffness and improvements in pain and inflammation are characteristic of the second stage ("frozen"). In the third stage ("thawing"), restriction of shoulder motion decreases, and ROM increases. Treatment should be adjusted to these stages. Recommendations include analgesics and joint injections in the first stage and physiotherapy in combination with manual therapy in the second and third stages. In cases of failure, passive exercise under interscalene block, manipulation under general anesthesia, or arthroscopic arthrolysis should be considered.
Collapse
Affiliation(s)
- A Schultheis
- Abteilung Arthroskopie - Sportorthopädie, Marienkrankenhaus Kaiserswerth, Düsseldorf
| | | | | |
Collapse
|
13
|
Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16:475-83. [PMID: 16788380 DOI: 10.1097/01.fpc.0000220562.67595.a5] [Citation(s) in RCA: 88] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The study aimed to investigate whether polymorphisms in genes of the EGFR signaling pathway are associated with clinical outcome in advanced colorectal cancer (CRC) patients treated with single-agent Cetuximab. Polymorphisms of interest in the EGFR pathway include: cyclin D1 (CCND1) A870G, cyclooxygenase 2 (Cox-2) G-765C, epidermal growth factor (EGF) A61G, epidermal growth factor receptor (EGFR) codon R497 K, EGFR CA dinucleotide repeat in intron 1, interleukin (IL)-8 T-251A and vascular endothelial growth factor (VEGF) C936 T gene polymorphisms. Thirty-nine metastatic CRC patients were enrolled in the IMCL-0144 trial and treated with single-agent Cetuximab. Using the polymerase chain reaction-restriction fragment length polymorphism method, gene polymorphisms of CCND1, COX-2, EGF, EGFR, IL-8 and VEGF were assessed from genomic DNA extracted from blood samples. A significant association was found between the CCND1 A870G polymorphism and overall survival in our 39 CRC subjects. Patients with the AA homozygous genotype survived for a median of 2.3 months [95% confidence interval (CI)=2.1-5.7], whereas those with any G allele (AG, GG genotype) survived for a median of 8.7 months (95% CI=4.4-13.5) (P=0.019, log-rank test). When we analysed the cyclin D1 and EGF polymorphisms together, patients with favourable genotypes (EGF any A allele and CCND1 any G allele) showed a median survival time of 12 months (95% CI=4.8-15.2), whereas patients with any two unfavourable genotypes (EGF GG or CCND1 AA) showed a median survived time of 4.4 months (95% CI=2.1-5.7) (P=0.004, log-rank test). The findings of this pilot study suggest that the cyclin D1 A870G and the EGF A61G polymorphisms may be useful molecular markers for predicting clinical outcome in CRC patients treated with single-agent Cetuximab.
Collapse
Affiliation(s)
- Wu Zhang
- Division of Medical Oncology, Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Nagashima F, Zhang W, Yang D, Gordon M, Schultheis A, Fazzone W, Azuma M, El-Khoueiry A, Iqbal S, Lenz HJ. Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3533] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3533 Background: Genetic polymorphisms in DNA repair and drug metabolism pathways have been shown to be associated with efficacy and toxicity in patients with metastatic colon cancer treated with 5-FU/oxaliplatin. Recent studies demonstrated in in vitro models that the neurotoxicity associated with oxaliplatin may be linked to an effect on neuronal voltage-gated sodium channels (VGSC). In vitro and in vivo models showed that increased VGSC alpha gene expression was associated with metastatic potential, proliferation and progression of breast and prostate cancer indicating a role in predicting toxicity and efficacy to chemotherapy. We tested the hypothesis whether VGSC gene polymorphisms may predict clinical outcome in a phase II study of combination oxaliplatin with 5-FU in patients with colorectal cancer refractory to 5-FU and/or irinotecan based chemotherapy. Methods: 173 patients were enrolled in this phase II study. 152 patients (male/female; 78/74, median age; 60), median follow up of 18.6 months, response rate of 19%, median time to tumor progression 4.2 months and median survival of 10.3 months. Grade 3/4 toxicity was seen in 60% with GI toxicity of 42% and Neurotoxicity of 11%. The dose of oxaliplatin was 130mg/m2 every 3 weeks and 5-FU was 200mg/m2/day CI for 10 weeks followed by 2 weeks rest. We tested the 12 VGSC genes polymorphisms (SCN1A, 1B, 1A1, 1A2, 1A3, 1A4, 1A5, 1A A3169G SNP, 1A C1702T Nonsense Mutation, 1A T1067A SNP, 1A C3637T SNP, SCN8A Ref SNP 303802). Genomic DNA was extracted from peripheral blood samples and polymorphisms were analyzed by PCR-based RFLP technique. Results: Patients with SCN1A T1067A SNP T/T genotype showed a significant better response rate (p=0.02, 21.9% [23/105] vs. 11.3% [5/44]), TTP (p=0.02, 4.6 months vs. 3.4 months), overall survival (p<.001, 12.3 months. vs. 8.0 months.), and frequency of grade 3/4 toxicity (p=.002) compare to patients with T/A genotype. No A/A genotype was observed. Conclusions: SCN1A gene polymorphism may be potential molecular marker for survival and toxicity in patients with colorectal cancer treated with 5-FU/oxaliplatin. In vitro studies are ongoing to identify the mechanism of resistance by SCN1A. [Table: see text]
Collapse
Affiliation(s)
- F. Nagashima
- University of Southern California, Los Angeles, CA
| | - W. Zhang
- University of Southern California, Los Angeles, CA
| | - D. Yang
- University of Southern California, Los Angeles, CA
| | - M. Gordon
- University of Southern California, Los Angeles, CA
| | | | - W. Fazzone
- University of Southern California, Los Angeles, CA
| | - M. Azuma
- University of Southern California, Los Angeles, CA
| | | | - S. Iqbal
- University of Southern California, Los Angeles, CA
| | - H. J. Lenz
- University of Southern California, Los Angeles, CA
| |
Collapse
|
15
|
Jäger M, Schultheis A, Westhoff B, Krauspe R. Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96). Anticancer Res 2005; 25:947-54. [PMID: 15868932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
BACKGROUND Since the first trial of chemotherapy in patients with osteosarcoma the survival rate has gradually improved. For more than two decades, most osteosarcoma patients from Germany, Austria and Switzerland have been treated according to the protocols of the Cooperative Osteosarcoma Study Group (COSS). The uniform treatment concept of a high-dose polychemotherapy pre- and postoperatively improved the survival rate of these patients significantly. One severe side-effect of COSS chemotherapy is multiple osteonecrosis. PATIENTS AND METHODS In this study the osteogenic stem cell potency of three different tissue types was elucidated after COSS-96 chemotherapy (high-risk arm). Mononuclear cells were obtained from the periosteum, cartilage and bone marrow of a 17-year-old female with a chondroblastic osteosarcoma. The cells were cultivated for 4 weeks in standard medium and stimulated for osteogenic differentiation after the second passage with dexamethasone, glycerolphosphate and ascorbine acid. Two weeks later, the cell cultures were analysed with respect to cell morphology and immunochemical stainings. RESULTS All cells cultures showed an osteoblastic regeneration potential measured by osteocalcin (OC), osteopontin (OP) and alkaline phosphatase (ALP) expression. Compared to other donor tissues and localizations, the fibula periosteum showed significantly higher osteoblast rates in vitro, whereas collagen II, CD34 and CD45 were not expressed in any culture. CONCLUSION The results of this study demonstrate the survival of mesenchymal progenitor cells in bone marrow during COSS-96 polychemotherapy, which allows for an osteogenic regeneration in vitro and potentially in vivo.
Collapse
Affiliation(s)
- M Jäger
- Department of Orthopaedics, Heinrich-Heine University Hospital Duesseldorf, D-40225 Duesseldorf, Germany.
| | | | | | | |
Collapse
|
16
|
Jäger M, Fischer J, Schultheis A, Lensing-Höhn S, Krauspe R. Extensive H+ release by bone substitutes affects biocompatibilityin vitro testing. J Biomed Mater Res A 2005; 76:310-22. [PMID: 16270341 DOI: 10.1002/jbm.a.30515] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Bone substitutes are widespread in orthopedic and trauma surgery to restore critical bony defects and/or promote local bone healing. Cell culture systems have been used for many years to screen biomaterials for their toxicity and biocompatibility. This study applies a human bone marrow cell culture system to evaluate the toxic in vitro effects of soluble components of different bone substitutes, which are already in clinical use. Different specimens of tricalcium phosphates (TCP) (Vitoss, Cerasorb), nondecalcified bovine bone (Lubboc), demineralized human bone matrices (DBM) (Grafton Flex/Putty), and collagen I/III matrix (ACI-Maix) were tested in Dulbecco's modified Eagle's medium (DMEM) and MesenCult culture solution and compared with a biomaterial-free cell culture. Biocompatibility parameters were cell viability evaluated by phase-contrast microscopy and laser flow cytometry, morphology, and the local H(+) release by bone substitutes. There were significant differences (p < 0.05) between the tested biomaterials and culture solutions. Collagen I/III, non-demineralized bovine bone, and TCP materials showed advantages for cell survival over other tested biomaterials (average values of vital cells/mL MesenCult/DMEM: Collagen I/III: 1090/1083; Vitoss: 893/483; Cerasorb: 471/523; Lubboc: 815/410; Grafton Putty: 61/44; Grafton Flex: 149/57). Especially the DBM materials lead to a significant decrease of pH, which is considered to be a major factor for cell death. DMEM culture solution supports cell survival for those bone substitutes that induce an alkaline reaction, whereas MesenCult media promotes cell vitality in biomaterials, which leads to an acidification of culture solution.
Collapse
Affiliation(s)
- M Jäger
- Department of Orthopedics, Heinrich-Heine University Hospital Duesseldorf, Moorenstrasse 5, D-40225 Duesseldorf, Germany.
| | | | | | | | | |
Collapse
|
17
|
Bunke HJ, Schultheis A, Meyer G, Düsel W. [Surgical revision of the pilonidal sinus with single shot antibiosis]. Chirurg 1995; 66:220-3. [PMID: 7750394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
For a therapy of the pilonidal sinus there are different surgical and non-surgical methods to be found in literature. In our surgical wing 140 male patients have been operated on this disease from September 1990 to July 1992. 16 cases out of these 140 were re-operations. Using a special surgical technique we applied the excision with a primary closure under single-shot antibiosis in 139 cases. By modifying this antibiosis prophylaxis we could reach a primary success healing rate of up to 96%. A retrospective study among our patients showed a recurrence rate of 5%.
Collapse
Affiliation(s)
- H J Bunke
- Abteilung für Chirurgie des Bundeswehrkrankenhaus Giessen
| | | | | | | |
Collapse
|
18
|
Mann H, Schultheis A, Homburg A, Brunner H, Rautenbach R. Anwendung und Grenzen der klinischen Hämofiltration. BIOMED ENG-BIOMED TE 1978. [DOI: 10.1515/bmte.1978.23.s1.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|